Synergistically enhanced CYP2B6 inducibility between a polymorphic mutation in CYP2B6 promoter and pregnane X receptor activation

Molecular Pharmacology

Volumn 78, Issue 4, 2010, Pages 704-713

  Li, Haishan ^a   Ferguson, Stephen S ^b   Wang, Hongbing ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b Life Technologies Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN ALPHA; CYTOCHROME P450 2B6; PHENOBARBITAL; PREGNANE X RECEPTOR; RIFAMPICIN; CYP2B6 PROTEIN, HUMAN; N DEMETHYLASE; STEROID RECEPTOR; UNSPECIFIC MONOOXYGENASE;

ARTICLE; BINDING SITE; GENE EXPRESSION; GENE MUTATION; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; HOMOZYGOSITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SINGLE NUCLEOTIDE POLYMORPHISM; ANIMAL; BIOSYNTHESIS; CHLOROCEBUS AETHIOPS; COMPARATIVE STUDY; COS 1 CELL LINE; DRUG EFFECTS; ENZYME INDUCTION; ENZYMOLOGY; GENETIC POLYMORPHISM; GENETICS; HEPG2 CELL LINE; LIVER CELL; METABOLISM; MUTATION; PROMOTER REGION; RENILLA;

ANIMALS; ARYL HYDROCARBON HYDROXYLASES; CERCOPITHECUS AETHIOPS; COS CELLS; CYTOCHROME P-450 CYP2B6; ENZYME INDUCTION; HEP G2 CELLS; HEPATOCYTES; HUMANS; MUTATION; OXIDOREDUCTASES, N-DEMETHYLATING; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC; RECEPTORS, STEROID; RENILLA; RIFAMPIN;

EID: 77957235034     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.110.065185     Document Type: Article

References (39)

1. Babu DA, Chakrabarti SK, Garmey JC, and Mirmira RG (2008) Pdx1 and BETA2/NeuroD1 participate in a transcriptional complex that mediates short-range DNA looping at the insulin gene. J Biol Chem 283:8164-8172.
2. Biason P, Masier S, and Toffoli G (2008) UGT1A1*28 and other UGT1A polymorphisms as determinants of irinotecan toxicity. J Chemother 20:158-165. (Pubitemid 351797053)
3. Chen Y and Goldstein JA (2009) The transcriptional regulation of the human CYP2C genes. Curr Drug Metab 10:567-578.
4. Code EL, Crespi CL, Penman BW, Gonzalez FJ, Chang TK, and Waxman DJ (1997) Human cytochrome P4502B6: interindividual hepatic expression, substrate specificity, and role in procarcinogen activation. Drug Metab Dispos 25:985-993.
5. Ekins S, Vandenbranden M, Ring BJ, Gillespie JS, Yang TJ, Gelboin HV, and Wrighton SA (1998) Further characterization of the expression in liver and catalytic activity of CYP2B6. J Pharmacol Exp Ther 286:1253-1259. (Pubitemid 29135537)
6. Faucette SR, Hawke RL, Lecluyse EL, Shord SS, Yan B, Laethem RM, and Lindley CM (2000) Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. Drug Metab Dispos 28:1222-1230.
7. Ferguson SS, Chen Y, LeCluyse EL, Negishi M, and Goldstein JA (2005) Human CYP2C8 is transcriptionally regulated by the nuclear receptors constitutive androstane receptor, pregnane X receptor, glucocorticoid receptor, and hepatic nuclear factor 4alpha. Mol Pharmacol 68:747-757. (Pubitemid 41206028)
8. Gatanaga H, Hayashida T, Tsuchiya K, Yoshino M, Kuwahara T, Tsukada H, Fujimoto K, Sato I, Ueda M, Horiba M, et al. (2007) Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26. Clin Infect Dis 45:1230-1237.
9. Goodwin B, Moore LB, Stoltz CM, McKee DD, and Kliewer SA (2001) Regulation of the human CYP2B6 gene by the nuclear pregnane X receptor. Mol Pharmacol 60:427-431. (Pubitemid 32781548)
10. Hagège H, Klous P, Braem C, Splinter E, Dekker J, Cathala G, de Laat W, and Forné T (2007) Quantitative analysis of chromosome conformation capture assays (3C-qPCR). Nature Protocols 2:1722-1733.
11. Hanna IH, Reed JR, Guengerich FP, and Hollenberg PF (2000) Expression of human cytochrome P450 2B6 in Escherichia coli: characterization of catalytic activity and expression levels in human liver. Arch Biochem Biophys 376:206-216.
12. Hesse LM, He P, Krishnaswamy S, Hao Q, Hogan K, von Moltke LL, Greenblatt DJ, and Court MH (2004) Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes. Pharmacogenetics 14:225-238.
13. Hesse LM, Venkatakrishnan K, Court MH, von Moltke LL, Duan SX, Shader RI, and Greenblatt DJ (2000) CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab Dispos 28:1176-1183.
14. Hidestrand M, Oscarson M, Salonen JS, Nyman L, Pelkonen O, Turpeinen M, and Ingelman-Sundberg M (2001) CYP2B6 and CYP2C19 as the major enzymes responsible for the metabolism of selegiline, a drug used in the treatment of Parkinson's disease, as revealed from experiments with recombinant enzymes. Drug Metab Dispos 29:1480-1484.
15. Hodgson E and Rose RL (2007) The importance of cytochrome P450 2B6 in the human metabolism of environmental chemicals. Pharmacol Ther 113:420-428.
16. Inoue K and Negishi M (2009) Early growth response 1 loops the CYP2B6 promoter for synergistic activation by the distal and proximal nuclear receptors CAR and HNF4alpha. FEBS Lett 583:2126-2130.
17. Jover R, Bort R, Gómez-Lechón MJ, and Castell JV (1998) Re-expression of C/EBP alpha induces CYP2B6, CYP2C9 and CYP2D6 genes in HepG2 cells. FEBS Lett 431:227-230.
18. Lamba V, Lamba J, Yasuda K, Strom S, Davila J, Hancock ML, Fackenthal JD, Rogan PK, Ring B, Wrighton SA, et al. (2003) Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression. J Pharmacol Exp Ther 307:906-922.
19. Lampe JW, Bigler J, Horner NK, and Potter JD (1999) UDP- glucuronosyltransferase (UGT1A1*28 and UGT1A6*2) polymorphisms in Caucasians and Asians: relationships to serum bilirubin concentrations. Pharmacogenetics 9:341-349. (Pubitemid 29376378)
20. Lang T, Klein K, Fischer J, Nüssler AK, Neuhaus P, Hofmann U, Eichelbaum M, Schwab M, and Zanger UM (2001) Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics 11:399-415.
21. Lang T, Klein K, Richter T, Zibat A, Kerb R, Eichelbaum M, Schwab M, and Zanger UM (2004) Multiple novel nonsynonymous CYP2B6 gene polymorphisms in Caucasians: demonstration of phenotypic null alleles. J Pharmacol Exp Ther 311:34-43. (Pubitemid 39287781)
22. Lau AJ and Chang TK (2009) Inhibition of human CYP2B6-catalyzed bupropion hydroxylation by Ginkgo biloba extract: effect of terpene trilactones and flavonols. Drug Metab Dispos 37:1931-1937.
23. LeCluyse EL, Alexandre E, Hamilton GA, Viollon-Abadie C, Coon DJ, Jolley S, and Richert L (2005) Isolation and culture of primary human hepatocytes. Methods Mol Biol 290:207-229.
24. Rodríguez-Antona C, Bort R, Jover R, Tindberg N, Ingelman-Sundberg M, Gómez-Lechón MJ, and Castell JV (2003) Transcriptional regulation of human CYP3A4 basal expression by CCAAT enhancer-binding protein alpha and hepatocyte nuclear factor-3 gamma. Mol Pharmacol 63:1180-1189.
25. Rotger M, Tegude H, Colombo S, Cavassini M, Furrer H, Décosterd L, Blievernicht J, Saussele T, Günthard HF, Schwab M, et al. (2007) Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals. Clin Pharmacol Ther 81:557-566.
26. Rüdiger JJ, Roth M, Bihl MP, Cornelius BC, Johnson M, Ziesche R, and Block LH (2002) Interaction of C/EBPalpha and the glucocorticoid receptor in vivo and in nontransformed human cells. FASEB J 16:177-184. (Pubitemid 34113011)
27. Schrem H, Klempnauer J, and Borlak J (2004) Liver-enriched transcription factors in liver function and development. Part II: the C/EBPs and D site-binding protein in cell cycle control, carcinogenesis, circadian gene regulation, liver regeneration, apoptosis, and liver-specific gene regulation. Pharmacol Rev 56:291-330. (Pubitemid 38720832)
28. Song CS, Echchgadda I, Seo YK, Oh T, Kim S, Kim SA, Cho S, Shi L, and Chatterjee B (2006) An essential role of the CAAT/enhancer binding protein-alpha in the vitamin D-induced expression of the human steroid/bile acid-sulfotransferase (SULT2A1). Mol Endocrinol 20:795-808.
29. Song X, Xie M, Zhang H, Li Y, Sachdeva K, and Yan B (2004) The pregnane X receptor binds to response elements in a genomic context-dependent manner, and PXR activator rifampicin selectively alters the binding among target genes. Drug Metab Dispos 32:35-42. (Pubitemid 38112533)
30. Spandidos A, Wang X, Wang H, and Seed B (2010) PrimerBank: a resource of human and mouse PCR primer pairs for gene expression detection and quantification. Nucleic Acids Res 38:D792-D799.
31. Stein B and Baldwin AS Jr (1993) Distinct mechanisms for regulation of the interleukin-8 gene involve synergism and cooperativity between C/EBP and NF-kappa B. Mol Cell Biol 13:7191-7198. (Pubitemid 23321171)
32. Stein B, Cogswell PC, and Baldwin AS Jr (1993) Functional and physical associations between NF-kappa B and C/EBP family members: a Rel domain-bZIP interaction. Mol Cell Biol 13:3964-3974. (Pubitemid 23187624)
33. Stresser DM and Kupfer D (1999) Monospecific antipeptide antibody to cytochrome P-450 2B6. Drug Metab Dispos 27:517-525.
34. Sueyoshi T, Kawamoto T, Zelko I, Honkakoski P, and Negishi M (1999) The repressed nuclear receptor CAR responds to phenobarbital in activating the human CYP2B6 gene. J Biol Chem 274:6043-6046. (Pubitemid 29111006)
35. Sugatani J, Yamakawa K, Tonda E, Nishitani S, Yoshinari K, Degawa M, Abe I, Noguchi H, and Miwa M (2004) The induction of human UDP- glucuronosyltransferase 1A1 mediated through a distal enhancer module by flavonoids and xenobiotics. Biochem Pharmacol 67:989-1000.
36. Swales K, Kakizaki S, Yamamoto Y, Inoue K, Kobayashi K, and Negishi M (2005) Novel CAR-mediated mechanism for synergistic activation of two distinct elements within the human cytochrome P450 2B6 gene in HepG2 cells. J Biol Chem 280:3458-3466. (Pubitemid 40223810)
37. Wang H, Faucette S, Sueyoshi T, Moore R, Ferguson S, Negishi M, and LeCluyse EL (2003) A novel distal enhancer module regulated by pregnane X receptor/constitutive androstane receptor is essential for the maximal induction of CYP2B6 gene expression. J Biol Chem 278:14146-14152. (Pubitemid 36799961)
38. Wang H and Tompkins LM (2008) CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme. Current drug metabolism 9:598-610.
39. Zukunft J, Lang T, Richter T, Hirsch-Ernst KI, Nussler AK, Klein K, Schwab M, Eichelbaum M, and Zanger UM (2005) A natural CYP2B6 TATA box polymorphism (-82T-> C) leading to enhanced transcription and relocation of the transcriptional start site. Mol Pharmacol 67:1772-1782. (Pubitemid 40594179)